Geron Corporation (GERN) has risen sharply, recording gains of 0.75% in the past 4 weeks. However, the stock has corrected -0.74% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.96% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 0.88% and the fifty day Moving Average is 0.3%. Geron Corporation has dropped 5.26% during the last three month period . Year-to-Date the stock performance stands at -44.21%.
Geron Corporation (GERN) : 3 Wall Street analysts covering Geron Corporation (GERN) believe that the average level the stock could reach for the short term is $7.5. The maximum price target given is $10 and the minimum target for short term is around $6, hence the standard deviation is calculated at $2.18.
Geron Corporation (NASDAQ:GERN): stock turned positive on Friday. Though the stock opened at $2.67, the bulls momentum made the stock top out at $2.76 level for the day. The stock recorded a low of $2.65 and closed the trading day at $2.7, in the green by 1.12%. The total traded volume for the day was 1,260,448. The stock had closed at $2.67 in the previous days trading.
Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.